Search

Your search keyword '"GEMZAR®"' showing total 4 results
Start Over Descriptor "GEMZAR®"
4 results on '"GEMZAR®"'

1. Treatment of Transformed Mycosis Fungoides with Intermittent Low-Dose Gemcitabine.

Author

Awar, Omar and Duvic, Madeleine

Subjects
*T cells, *MYCOSIS fungoides, *LYMPHOMAS, *LYMPHOPROLIFERATIVE disorders, *CELL proliferation
Abstract

The malignant helper T cells of mycosis fungoides, a type of cutaneous T cell lymphoma, are capable of transforming into large cerebriform cells. Large cell transformation usually renders the disease more resistant to treatment and prone to relapse. Currently investigated treatment modalities for transformed mycosis fungoides are few and include phototherapy, chemotherapy, biologic response modification, targeted molecular therapy and combinations thereof. A tolerable and reliable modality has yet to be identified. Gemcitabine, a novel purine analogue, is gaining recognition as a potent agent for advanced nontransformed cutaneous T cell lymphoma. Here we present a brief review of the literature with 3 illustrative cases that additionally reveal gemcitabine monotherapy to be a practical, safe and efficacious option for mycosis fungoides that has undergone large cell transformation. Copyright © 2008 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

2. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: Biodistribution, pharmacokinetic features and in vivo antitumor activity

Author

Sebastiano Filetti, Donatella Paolino, Christian Celia, Giuseppe Costante, Leda Racanicchi, Diego Russo, Michelangelo Iannone, Elena Trapasso, Massimo Fresta, Efisio Puxeddu, and Donato Cosco

Subjects
aro cell xenograft model, biodistribution, gemcitabine, pharmacokinetic, unilamellar pegylated liposomes, Biodistribution, Chemistry, Pharmaceutical, Metabolite, Pharmaceutical Science, Antineoplastic Agents, Mice, SCID, Pharmacology, Deoxycytidine, Polyethylene Glycols, PEGylated unilamellar liposomes, Mice, In vivo antitumor activity, chemistry.chemical_compound, Therapeutic index, Pharmacokinetics, Floxuridine, Mice, Inbred NOD, In vivo, medicine, Animals, GEMZAR®, Tissue Distribution, Unilamellar Liposomes, Liposome, Chemistry, Gemcitabine, Pharmacokinetic features, Raloxifene Hydrochloride, Liposomes, Half-Life, medicine.drug
Abstract

The systemic efficacy of the chemotherapeutic agents presently used to treat solid tumors is limited by their low therapeutic index. Previously, our research group improved the in vitro antitumoral activity of gemcitabine, an anticancer agent rapidly deaminated to the inactive metabolite 2',2'-difluorodeoxyuridine, entrapping it into unilamellar pegylated liposomes made up of 1,2-dipalmitoyl-snglycero-3-phosphocholine monohydrate/cholesterol/N-(carbonyl-methoxypolyethylene glycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (6:3:1 molar ratio). In this work, we investigated the in vivo efficiency of the gemcitabine liposomal formulation (5mg/kg) with respect to the antitumoral commercial product GEMZAR (50mg/kg) on an anaplastic thyroid carcinoma xenograft model obtaining similar effects in terms of inhibition of tumor mass proliferation after 4weeks of treatment. The investigation of the carrier biodistribution and the drug pharmacokinetic profile furnished the rationalization of the efficacy of the vesicular system containing the active compound 10-fold less concentrated; in fact, liposomes promoted the concentration of the drug inside the tumor and they increased its plasmatic half-life. In addition, no signs of blood toxicity were observed when vesicular devices of effective doses of the drug were used.

Published
2010
Full Text
View/download PDF

3. Inyección de gemcitabina.

Abstract

Copyright of ASHP Patient Medication Information - Spanish Version is the property of American Society of Health System Pharmacists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022

4. Gemcitabine Injection.

Abstract

Gemcitabine is used in combination with other chemotherapy drugs to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) and breast cancer that has not improved or that has worsened after treatment with other medications. Gemcitabine is used in combination with other chemotherapy drugs to treat a type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body and cannot be treated with surgery. Gemcitabine is also used to treat cancer of the pancreas that has spread to other parts of the body and has not improved or worsened after treatment with another medication. Gemcitabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in your body. [ABSTRACT FROM PUBLISHER]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results